XCOPRI (nda212839)- (12.5MG,25MG,50MG,100MG,150MG,200MG)

Generic Name	CENOBAMATE	Innovator	SK LIFE
Dosage	12.5MG,25MG,50MG,100MG,150MG,200MG
ParaIV Filing	Yes	505(b)2 Filing	No
Last Patent Expiry	2039-Jun-16	NCE Excl Expiry	2025-Mar-10
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	5

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
12.5MG	**	**	Up	-	-
25MG	**	**	-	-	-
50MG	**	**	Up	-	-
100MG	**	**	Up	-	-
150MG	**	**	Up	-	-
200MG	**	**	Up	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
Yes	0

Manufacturing Details of XCOPRI